Oriental Aromatics Ltd

- The company has already taken term loans for ongoing projects: Downfield project has only Rs. 20 crore outstanding, and Mahad project’s highest debt would be Rs. 70 crore. - Peak debt for the current financial year is expected at Rs. 200 crore for the parent company and Rs. 80 crore for the subsidiary, totaling Rs. 280 crore at the group level. - Around Rs. 85 crore of the debt is long-term (term loans), and the rest is working capital debt, supported by inventories. - The management states they are conservative with debt and have no indication of raising additional equity or significantly increasing debt beyond planned levels. - Future CAPEX beyond current projects may happen but has not been detailed; earlier planned CAPEX has been implemented. - They aim to further reduce debt over time and maintain healthy debt ratios. There are no announcements of new fundraising through debt or equity at present.

- The company has completed major CAPEX projects, including the commissioning of a Brownfield hydrogenation plant at Vadodara (commissioned July 2020) and a greenfield project in Mahad, which is in advanced commissioning and expected to contribute from the second half of FY 2024-2025. - The hydrogenation facility is multi-product, targeting 6-7 products with ~700 tons annual capacity, expected to reach 70-80% utilization within 4-5 quarters. - Mahad plant is initially a single product plant with ~250 metric tons capacity, aiming for full stabilization 2-3 quarters after going live. - Incremental depreciation from new facilities expected to be Rs. 8-10 crores annually. - Peak group-level debt expected at Rs. 280 crores for ongoing expansions. - Future CAPEX beyond these projects is possible but currently unspecified, with a cautious and conservative approach to funding and debt management. - The company is optimistic about capturing growth opportunities driven by new capacities and "China Plus One" customer shifts.

- Expected peak revenue of around ₹1200 crore post full capacity utilization of new plants (next few quarters). - New hydrogenation facility (multi-product) aimed at 700 tons annual capacity, expected to reach 70-80% utilization within 4-5 quarters. - Mahad single product plant phased for 250 metric tons with a stabilization timeline of 2-3 quarters post-launch. - Anticipated top line growth from new capacities starting contribution from Q3 FY 2024-25 (Baroda) and second half FY 2024-25 (Mahad). - Continuous product approvals and phased growth expected; timeline for products moving from marginal to major supplier status is 2-3.5 years. - India and "China Plus One" strategy considered positive drivers for growth. - Management cautiously optimistic about volume and revenue growth but refrains from exact percentage guidance currently due to approvals and pricing finalization.

- The company expects to achieve a top line of approximately Rs. 1200 crores after the new plants reach full capacity over the next 2-3 quarters. - EBITDA guidance for the current year stands at 10% to 12%, with confidence in meeting or exceeding this range over the next two quarters. - There is optimism for both volume growth and better realizations across divisions, potentially driving top line growth. - The company aims for steady-state growth with ongoing new product launches and capacity expansions contributing to profitability. - Long-term EBITDA margin guidance remains at 14% to 17%, expected to normalize as new CAPEX-related efficiencies come into play. - Peak debt is projected around Rs. 280 crores at the group level, managed conservatively without compromising financial prudence. - Cautious optimism is expressed around India’s growing market and China Plus One strategy enhancing growth opportunities.

- The transcript does not explicitly mention the current or expected order book or pending orders in specific numeric terms. - However, it indicates healthy demand across divisions and positive outlook for the next 2-3 quarters. - The fragrance division continues to acquire new customers and sees growth from new business opportunities. - Increased allocations have been received from key customers for the second half of FY 2024-25, signaling strong order momentum. - New plants (hydrogenation plant at Vadodara and Greenfield plant at Mahad) are expected to contribute to the top line from the second half of FY 2024-25, implying an improving order pipeline. - The company is in a phase of product approval and volume ramp-up, indicating ongoing and future product orders are being finalized and will contribute progressively.